Home › Companies › Aquestive Therapeutics, Inc. › 2025-2026

Aquestive Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Aquestive Therapeutics, Inc.’s Form 8-K, filed June 10, 2026 (Item 5.07 on EDGAR). Page generated October 25, 2026.

  • 8Reported items
  • 163Asset managers
  • 767Fund votes
  • June 10, 2026Meeting date

Results at a glance

Meeting of June 10, 2026: 4 items on Aquestive Therapeutics, Inc.’s Form 8-K, filed June 10, 2026: 2 approved · 2 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2024-2025 2025-2026

Explore Aquestive Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Aquestive Therapeutics, Inc.

These tallies are Aquestive Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Aquestive Therapeutics, Inc. — official shareholder meeting results, meeting held June 10, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: John S. Cochran 36,914,899--5,680,845 ---- —Not verified—
Elect Director: Abigail L. Jenkins 39,094,166--3,501,578 ---- —Not verified—
2. Proposal to approve, on a non-binding advisory basis, executive compensation 37,798,6093,192,3811,604,754 --37,465,582 92%Approved—
3. Appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 78,804,323910,690346,313 ---- 99%Approved—

Source: Aquestive Therapeutics, Inc., Form 8-K, filed with the SEC on June 10, 2026 — read the filing on EDGAR.

How asset managers voted at the Aquestive Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 163 asset managers that disclosed a Aquestive Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Aquestive Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the…: Abigail L. Jenkins

No official matchDIRECTOR ELECTIONS

97% of fund votes cast · no official result

FOR
Details: description as filed, votes by 27 asset managers

Description as filed by funds: To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Directors, each to serve for a three-year term until the Company's 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Abigail L. Jenkins

The 27 asset managers below reported 4,975,620 for, 150,113 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 4,975,620WITHHOLD: 150,113
Largest asset managers voting on “To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Di” at Aquestive Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,271,2970 00For
WASATCH FUNDS TRUST856,6230 00For
Fidelity638,9190 00For
Equitable29,3790 053,980Mixed
State Street80,3920 059For
Lincoln Financial64,0000 00For
ProShares00 028,350Withhold
AIG/SunAmerica00 015,722Withhold
AQR00 015,077Withhold
DWS00 014,058Withhold
Pacific Life12,0530 00For
Voya9,5010 00For
Calvert00 07,276Withhold
Blackstone Alternative Investment Funds00 05,200Withhold
Principal00 05,060Withhold
Goldman Sachs4,6410 00For
Morgan Stanley00 04,028Withhold
PENN SERIES FUNDS INC2,8000 00For
TIAA2,2870 00For
Brinker Capital Destinations Trust2,1650 00For
Nationwide1,3320 00For
Guggenheim00 0785Withhold
Direxion Shares ETF Trust00 0308Withhold
Victory Capital00 0208Withhold
T. Rowe Price1340 00For

Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.

2. To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of…: Gregory B. Brown, M.D.

No official matchDIRECTOR ELECTIONS

99.8% of fund votes cast · no official result

FOR
Details: description as filed, votes by 27 asset managers

Description as filed by funds: To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Directors, each to serve for a three-year term until the Company's 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Gregory B. Brown, M.D.

The 27 asset managers below reported 5,118,421 for, 7,312 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 5,118,421WITHHOLD: 7,312
Largest asset managers voting on “To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Di” at Aquestive Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,271,2970 00For
WASATCH FUNDS TRUST856,6230 00For
Fidelity638,9190 00For
Equitable83,3590 00For
State Street80,4150 036For
Lincoln Financial64,0000 00For
ProShares28,3500 00For
AIG/SunAmerica15,7220 00For
AQR15,0770 00For
DWS14,0580 00For
Pacific Life12,0530 00For
Voya9,5010 00For
Calvert00 07,276Withhold
Blackstone Alternative Investment Funds5,2000 00For
Principal5,0600 00For
Goldman Sachs4,6410 00For
Morgan Stanley4,0280 00For
PENN SERIES FUNDS INC2,8000 00For
TIAA2,2870 00For
Brinker Capital Destinations Trust2,1650 00For
Nationwide1,3320 00For
Guggenheim7850 00For
Direxion Shares ETF Trust3080 00For
Victory Capital2080 00For
T. Rowe Price1340 00For

Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.

3. To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the…: John S. Cochran

No official matchDIRECTOR ELECTIONS

80% of fund votes cast · no official result

FORWITHHOLD
Details: description as filed, votes by 27 asset managers

Description as filed by funds: To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Directors, each to serve for a three-year term until the Company's 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: John S. Cochran

The 27 asset managers below reported 4,109,472 for, 1,016,261 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 4,109,472WITHHOLD: 1,016,261
Largest asset managers voting on “To elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II members of the Board of Di” at Aquestive Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,271,2970 00For
WASATCH FUNDS TRUST00 0856,623Withhold
Fidelity638,9190 00For
Equitable29,3790 053,980Mixed
State Street80,3680 083For
Lincoln Financial64,0000 00For
ProShares00 028,350Withhold
AIG/SunAmerica00 015,722Withhold
AQR00 015,077Withhold
DWS00 014,058Withhold
Pacific Life12,0530 00For
Voya00 09,501Withhold
Calvert00 07,276Withhold
Blackstone Alternative Investment Funds00 05,200Withhold
Principal00 05,060Withhold
Goldman Sachs4,6410 00For
Morgan Stanley00 04,028Withhold
PENN SERIES FUNDS INC2,8000 00For
TIAA2,2870 00For
Brinker Capital Destinations Trust2,1650 00For
Nationwide1,3320 00For
Guggenheim00 0785Withhold
Direxion Shares ETF Trust00 0308Withhold
Victory Capital00 0208Withhold
T. Rowe Price1340 00For

Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.

4. Elect Director: Abigail L. Jenkins

Outcome not verifiedDIRECTOR ELECTIONS

Combines 5 wordings of this item as funds reported it.

99.8% of fund votes cast · no official result

FOR
Details: description as filed, votes by 15 asset managers

Description as filed by funds: Elect Abigail Jenkins

The 15 asset managers below reported 2,672,932 for, 2,720 withheld, 571 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 2,672,932ABSTAIN: 571WITHHOLD: 2,720
Largest asset managers voting on “Elect Abigail Jenkins” at Aquestive Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock1,020,8350 00For
Bridge Builder Trust723,4820 00For
Charles Schwab267,4010 00For
Simplify Exchange Traded Funds234,2790 00For
Federated Hermes156,3500 00For
Russell Investments97,5190 00For
QUANTITATIVE MASTER SERIES LLC87,9400 00For
Global X48,2590 00For
SEI15,4000 00For
Vanguard11,4730 100For
Venerable Variable Insurance Trust7,1260 00For
Eleva Capital SAS00 02,720Withhold
Nationwide2,3010 00For
Advisors' Inner Circle Fund III5670 00For
John Hancock00 5610Abstain

5. Elect Gregory B. Brown

No official matchDIRECTOR ELECTIONS

Combines 5 wordings of this item as funds reported it.

99.6% of fund votes cast · no official result

FOR
Details: votes by 15 asset managers

The 15 asset managers below reported 2,668,020 for, 8,200 withheld, 3 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 2,668,020ABSTAIN: 3WITHHOLD: 8,200
Largest asset managers voting on “Elect Gregory B. Brown” at Aquestive Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock1,020,8350 00For
Bridge Builder Trust723,4820 00For
Charles Schwab267,4010 00For
Simplify Exchange Traded Funds234,2790 00For
Federated Hermes156,3500 00For
Russell Investments97,5190 00For
QUANTITATIVE MASTER SERIES LLC87,9400 00For
Global X48,2590 00For
SEI15,4000 00For
Vanguard3,8470 37,633Mixed
Venerable Variable Insurance Trust7,1260 00For
Eleva Capital SAS2,7200 00For
Nationwide2,3010 00For
Advisors' Inner Circle Fund III00 0567Withhold
John Hancock5610 00For

6. Elect Director: John S. Cochran

Outcome not verifiedDIRECTOR ELECTIONS

Combines 5 wordings of this item as funds reported it.

93% of fund votes cast · no official result

FOR
Details: description as filed, votes by 15 asset managers

Description as filed by funds: Elect John S. Cochran

The 15 asset managers below reported 2,496,428 for, 179,224 withheld, 571 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 2,496,428ABSTAIN: 571WITHHOLD: 179,224
Largest asset managers voting on “Elect John S. Cochran” at Aquestive Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock1,020,8350 00For
Bridge Builder Trust723,4820 00For
Charles Schwab267,4010 00For
Simplify Exchange Traded Funds234,2790 00For
Federated Hermes156,3500 00For
Russell Investments00 097,519Withhold
QUANTITATIVE MASTER SERIES LLC87,9400 00For
Global X00 048,259Withhold
SEI00 015,400Withhold
Vanguard3,8400 107,633Mixed
Venerable Variable Insurance Trust00 07,126Withhold
Eleva Capital SAS00 02,720Withhold
Nationwide2,3010 00For
Advisors' Inner Circle Fund III00 0567Withhold
John Hancock00 5610Abstain

7. 2. Proposal to approve, on a non-binding advisory basis, executive compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%
FOR: 37,798,609AGAINST: 3,192,381
Details: description as filed, official tally, votes by 161 asset managers

Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

Aquestive Therapeutics, Inc.’s own tally for this item (“2. Proposal to approve, on a non-binding advisory basis, executive compensation”): 37,798,609 for, 3,192,381 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 39 asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at Aquestive Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,282,7697 40For
BlackRock1,020,8350 00For
WASATCH FUNDS TRUST856,6230 00For
Bridge Builder Trust723,4820 00For
Fidelity638,9190 00For
Charles Schwab267,4010 00For
Simplify Exchange Traded Funds234,2790 00For
Federated Hermes156,3500 00For
Russell Investments97,5190 00For
QUANTITATIVE MASTER SERIES LLC87,9400 00For
Equitable83,3590 00For
State Street80,4492 00For
Lincoln Financial64,0000 00For
Global X48,2590 00For
ProShares28,3500 00For
AIG/SunAmerica15,7220 00For
SEI15,4000 00For
AQR15,0770 00For
DWS14,0580 00For
Pacific Life12,0530 00For
Voya9,5010 00For
Calvert7,2760 00For
Venerable Variable Insurance Trust7,1260 00For
Blackstone Alternative Investment Funds5,2000 00For
Principal5,0600 00For

Fund voting reports, all 39 managers: 7,799,125 for, 106 against, 4 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 137 asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at Aquestive Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP7,426,4710 00For
Samsara BioCapital, LLC2,500,0000 00For
BlackRock1,487,26141,501 1,2690For
Blue Owl Capital Holdings LP1,207,9320 00For
Janney Montgomery Scott LLC1,088,1100 00For
Federated Hermes939,6080 00For
State Street925,3064,188 00For
WASATCH ADVISORS LP877,2890 00For
GEODE CAPITAL MANAGEMENT, LLC757,1390 00For
Two Sigma688,4910 00For
BALYASNY ASSET MANAGEMENT L.P.659,7720 00For
DAFNA Capital Management LLC550,9150 00For
Bracebridge Capital, LLC459,2160 00For
STIFEL NICOLAUS & CO INC \MO\385,5620 00For
Northern Trust369,1410 00For
Charles Schwab267,4190 00For
Latash Investments, LLC243,1340 00For
Wellington207,2550 00For
Russell Investments193,1460 00For
Vanguard170,9910 00For
MELLON INVESTMENTS Corp128,6960 00For
Citadel110,1930 00For
MARSHALL WACE, LLP99,0860 00For
Bleakley Financial Group, LLC92,3580 00For
Sanctuary Advisors, LLC87,9690 00For

Institutional-manager reports, all 137 managers: 23,069,145 for, 100,433 against, 1,446 abstained. Showing the 25 largest; see all in the interactive database.

8. 3. Appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%
FOR: 78,804,323AGAINST: 910,690
Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Aquestive Therapeutics, Inc.’s own tally for this item (“3. Appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026”): 78,804,323 for, 910,690 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 7,799,462 for, 2,495 against, 1,000 abstained.

FOR
FOR: 7,799,462AGAINST: 2,495ABSTAIN: 1,000
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR” at Aquestive Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,280,2982,483 00For
BlackRock1,020,8350 00For
WASATCH FUNDS TRUST856,6230 00For
Bridge Builder Trust723,4820 00For
Fidelity638,9190 00For
Charles Schwab267,4010 00For
Simplify Exchange Traded Funds234,2790 00For
Federated Hermes156,3500 00For
Russell Investments97,5190 00For
QUANTITATIVE MASTER SERIES LLC87,9400 00For
Equitable83,3590 00For
State Street80,43912 00For
Lincoln Financial64,0000 00For
Global X48,2590 00For
ProShares28,3500 00For
AIG/SunAmerica15,7220 00For
SEI15,4000 00For
AQR15,0770 00For
DWS14,0580 00For
Pacific Life12,0530 00For
Voya9,5010 00For
Calvert7,2760 00For
Venerable Variable Insurance Trust7,1260 00For
Blackstone Alternative Investment Funds5,2000 00For
Principal5,0600 00For

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

Largest Aquestive Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 125,450,119 shares outstanding at the time of that meeting.

Fund voting reports: top Aquestive Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 2.62%
2BlackRock 0.81%
3WASATCH FUNDS TRUST 0.68%
4Bridge Builder Trust 0.58%
5Fidelity 0.51%
6Charles Schwab 0.21%
7Simplify Exchange Traded Funds 0.19%
8Federated Hermes 0.12%
9Russell Investments 0.08%
10QUANTITATIVE MASTER SERIES LLC 0.07%
Institutional-manager reports: top Aquestive Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.”, 2025-2026
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 5.92%
2Samsara BioCapital, LLC 1.99%
3BlackRock 1.22%
4Blue Owl Capital Holdings LP 0.96%
5Janney Montgomery Scott LLC 0.87%
6Federated Hermes 0.75%
7State Street 0.74%
8WASATCH ADVISORS LP 0.70%
9GEODE CAPITAL MANAGEMENT, LLC 0.60%
10Two Sigma 0.55%

Reported Aquestive Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Aquestive Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder % outstanding Disclosure
Douglas K. Bratton 7.86% DEF14A
BlackRock 5.99% 13F
RTW Investments, LP 4.98% DEF14A
Vanguard Group 4.70% 13F
MonoLine RX II, L.P. 2.77% DEF14A
Daniel Barber 2.45% DEF14A
MonoLine RX III, L.P. 2.12% DEF14A
State Street 2.03% 13F
Geode Capital 1.92% 13F
MonoLine Partners, L.P. 1.42% DEF14A

Percentages above are of 125,450,119 shares outstanding, as reported by Aquestive Therapeutics, Inc. on its Form 10-Q dated May 11, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Aquestive Therapeutics, Inc.’s 10-Q dated May 11, 2026. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.

At Aquestive Therapeutics, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 163 asset managers reported how they voted in their SEC Form N-PX filings, covering 767 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — Aquestive Therapeutics, Inc.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Aquestive Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2026.

Aquestive Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.